Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Sequencing and functional characterization of SCARB1 variants in subjects with extreme HDL cholesterol levels

  • Gracia-Rubio, Irene
  • Benito-Vicente, Asier
  • Lamiquiz-Moneo, Itziar
  • Bea, Ana M.
  • Marco Benedí, Victoria
  • Cabrera-Antón, Endika
  • Martín, César
  • Civiera, Fernando
  • Cenarro, Ana
[Background] Rare variants in SCARB1, which encodes the high-density lipoprotein (HDL) receptor scavenger receptor class B type 1 (SR-B1), are hypothesized to drive unexplained extreme levels of plasma HDL cholesterol (HDL-C)., [Objective] We sequenced and phenotypically correlated SCARB1 by analyzing individuals with extreme HDL-C levels and characterizing the functional consequences of rare identified variants., [Methods] SCARB1 was Sanger-sequenced in 96 unrelated participants with extreme HDL-C levels. Clinical, biochemical, and anthropometric data were compared between groups. Bioinformatic tools were used to predict the functional impact of all detected variants. Familial analyses of predicted damaging in silico or not previously described variants was assessed, and HDL uptake was quantified by flow cytometry in HEK293 cells expressing rare SCARB1 variants showing a suggestive pattern of familial segregation., [Results] Compared with the high-HDL-C group, low-HDL-C subjects exhibited lower low-density lipoprotein cholesterol and total cholesterol but higher triglycerides, higher body mass index, and a greater frequency of atherosclerotic cardiovascular disease events. Twenty-five SCARB1 variants were identified; 4 of them, c.-177G>T, p.(Thr118Ser), c.843-982G>A and p.(Thr378Met), were predicted to be deleterious. The missense changes p.(Thr118Ser) and p.(Thr378Met) showed a suggestive pattern of segregation with high HDL-C in available pedigrees. Cells expressing p.(Thr378Met) SCARB1 variant showed a reduction in HDL uptake vs wild-type., [Conclusion] Rare predicted damaging in silico variant in SCARB1, p.(Thr378Met), impairs SR-B1-mediated HDL uptake and associates with high HDL-C levels, highlighting SCARB1 as a candidate gene for genetic screening in dyslipidemic patients., This study was supported by grants from the Spanish Ministry of Economy and Competitiveness PI22/01595 and CIBERCV; and Gobierno de Aragón B14-23R. These projects are cofinanced by Instituto de Salud Carlos III and the European Regional Development Fund (ERDF) of the European Union ‘‘A way to make Europe” and Grupos Consolidados Gobierno Vasco 2021, grant number 449IT1720‐22 and Proyectos de Generación de Conocimiento from the Ministerio de Ciencia, Innovación y Universidades, under the grant PID2022‐136788OB‐I00., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Association of HDL cholesterol with all-cause and cardiovascular mortality in primary hypercholesterolemia

  • Bea, Ana M.
  • González-Guerrero, Anton
  • Cenarro, Ana
  • Lamiquiz-Moneo, Itziar
  • Climent, Elisenda
  • Jarauta, Estibaliz
  • Gracia-Rubio, Irene
  • Benaiges, David
  • Laclaustra, Martín
  • Tejedor, Teresa
  • Pedro-Botet, Juan
  • Civeira, Fernando
  • Marco-Benedí, Victoria
Background and aims. Recent reports have shown that subjects with high high-density lipoprotein cholesterol (HDLc) levels are paradoxically at increased risk for all-cause and cardiovascular mortality. The aim was to study the association of HDLc concentration with mortality in subjects with high cholesterol. Methods. We analyzed total mortality, cardiovascular mortality, and non-cardiovascular mortality in a cohort of 2992 subjects with primary hypercholesterolemia, who were followed for 10.2 years (range 1–25 years), with a total of 30,602 subject-years of follow-up. Results. During follow-up, 168 subjects died, with 52 (13.7 %), 105 (4.80 %), and 11 (2.60 %) in the low, normal, and high HDLc groups, respectively (p < 0.001). The risk of death was 2.89 times higher (95 % confidence interval (CI), 1.50–5.57, p < 0.001) in subjects in the low HDLc group compared to those in the high HDLc group and 1.48 times higher (95 % CI 0.80–2.76, p = 0.214) in the normal HDLc group compared to the high HDLc group. However, HDLc concentration and HDLc groups based on HDLc concentration were not independently associated with mortality in Cox regression analysis. Cardiovascular and non-cardiovascular mortalities showed similar results. Conclusions. All types of mortality were lower in subjects with primary hypercholesterolemia and with high HDLc in univariate analysis. Elevated HDLc was not associated with total, cardiovascular, and non-cardiovascular mortality when adjusted for major cardiovascular risk factors.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

APOE p.(Leu167del) variant in hypercholesterolemia: Prevalence & phenotypic expression

  • Bello-Álvarez, Daniel
  • Cenarro, Ana
  • Bea, Ana M.
  • Marco-Benedí, Victoria
  • Jarauta, Estíbaliz
  • Ortiz-Palma, Pedro
  • Ortega, Emilio
  • González-Lleó, Ana M.
  • Civeira, Fernando
BACKGROUND.The APOE p.(Leu167del) variant has been identified as a rare cause of autosomal dominant hypercholesterolemia. A comprehensive phenotypic profile of carriers remains undefined, and its frequency has not been systematically studied. OBJECTIVE To characterize the phenotypic differences between p.(Leu167del) carriers among individuals with primary hypercholesterolemia and those with familial hypercholesterolemia (FH), and to estimate the variant's frequency in different populations. MEDTHODS Phenotypic differences were assessed from the Lipid Unit cohort of the Hospital Universitario Miguel Servet (HUMS, n = 6489). The allele frequency of the p.(Leu167del) variant was estimated using data from the HUMS and Aragon Workers Health Study (AWHS, n = 5678), a cohort of working adults, and international cohorts: GnomAD (n ≈ 807,162), TOPMed (n ≈ 180,000), 100 K Genomes Project (n ≈ 85,000). To characterize the profile of carriers, data from the HUMS cohort and a systematic review of the published literature were also used. RESULTS Carriers showed significantly higher high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, and non-HDL cholesterol and lower lipoprotein(a) [Lp(a)] concentrations compared to noncarriers with primary hypercholesterolemia. In comparison with FH patients carrying LDL receptor (LDLR), apolipoprotein B (APOB), or proprotein convertase subtilisin/kexin type 9 ( PCSK9 ) variants, carriers displayed higher triglycerides and HDL cholesterol but lower LDL cholesterol and Lp(a). The APOE p.(Leu167del) frequency is approximately 1 in 12,000 individuals in the general population and about 2.5% of FH. CONCLUSION The study confirmed the association of APOE p.(Leu167del) with hypercholesterolemia but with lower LDL cholesterol than subjects with FH. These findings support p.(Leu167del) as a cause of FH and its inclusion in the genetic screening for FH, particularly in Caucasian populations
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Classification, prevalence and cardiovascular risk of different types of hypercholesterolemia

  • Civeira, Fernando
  • Jarauta, Estíbaliz
  • Marco-Benedí, Victoria
  • Bea, Ana M.
  • Mateo-Gallego, Rocío
  • Lamiquiz-Moneo, Itziar
  • Gracia-Rubio, Irene
  • Bello-Álvarez, Daniel
  • Laclaustra, Martín
  • Tejedor, María Teresa
  • Olmos, Salvador
  • Cenarro, Ana
Introduction and objectives: The frequency, clinical characteristics and risk of atherosclerotic cardiovascular disease (ASCVD) of the different types of hypercholesterolemia are not well established. The primary and secondary objectives of this study were to determine the cause of hypercholesterolemia and whether the cause confers a different ASCVD prognosis. Methods: The analysis included 3474 probands with primary hypercholesterolemia, of whom 3283 (94.8%) were followed up for 9.33 ± 5.8 years for ASCVD. Genetic analysis of familial hypercholesterolemia (FH) genes, polygenic risk score for ypercholesterolemia, and lipid concentrations, including lipoprotein(a), were used to classify hypercholesterolemia. Results: The diagnoses were heterozygous FH, n = 400 (11.5%); hyperlipoproteinemia(a), n = 181 (5.2%); polygenic hypercholesterolemia, n = 434 (12.5%); hyperlipoproteinemia(a) plus polygenic hypercholesterolemia, n = 128 (3.7%); multifactorial, n = 1562 (45.0%); and idiopathic, n = 769 (22.1%). At baseline, low-density lipoprotein cholesterol levels were higher in heterozygous FH, and the prevalence of ASCVD was higher in hyperlipoproteinemia(a). Other clinical and biochemical characteristics did not differ among hypercholesterolemia subgroups. The survival rate was lower in participants with hyperlipoproteinemia(a) than in the other hypercholesterolemia groups (P = .001). Variables independently associated with ASCVD events during follow-up were age, male sex, the presence of ASCVD, diabetes or hypertension at baseline, current smoking, lipoprotein(a) concentration, and high-density lipoprotein cholesterol concentration, the latter being inversely associated with ASCVD events. Total mortality was independent of the type of hypercholesterolemia. Conclusions: Genetic hypercholesterolemia has a worse prognosis for ASCVD than nongenetic hypercholesterolemia. Among individuals with genetic hypercholesterolemia, those with elevated lipoprotein(a) have the worst prognosis. Conventional lipidowering treatment for low-density lipoprotein cholesterol appears to be less effective in hypercholesterolemia due to hyperlipoproteinemia (a) than in other forms of hypercholesterolemia.